Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Xortx Therapeutics Inc (XRX.CN)

Xortx Therapeutics Inc (XRX.CN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 41,297
  • Shares Outstanding, K 12,291
  • Annual Sales, $ 0 K
  • Annual Income, $ -1,285 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta 0.40
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 12.44
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.35
  • Most Recent Earnings $-0.02 on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield (Fwd) N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector N/A
  • INDUSTRY GROUPING N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.070 +56.35%
on 10/21/21
7.900 -39.24%
on 10/05/21
-2.200 (-31.43%)
since 10/04/21
3-Month
2.040 +135.29%
on 08/05/21
10.200 -52.94%
on 09/08/21
+2.640 (+122.22%)
since 08/04/21
52-Week
1.140 +321.05%
on 12/11/20
10.200 -52.94%
on 09/08/21
+3.180 (+196.30%)
since 11/04/20

Most Recent Stories

More News
XORTX to Present at "Zoom With LD MICRO"

CALGARY, AB / ACCESSWIRE / March 16, 2021 / XORTX Therapeutics Inc. ("XORTX" or the "Company") (CSE:XRX) (OTCQB:XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive...

XRTXF : 0.4387 (-1.50%)
XRX.CN : 4.800 (unch)
XORTX to Present and Participate in the Sachs 14th Annual European Life Sciences CEO Forum 2021

CALGARY, AB / ACCESSWIRE / March 9, 2021 / XORTX Therapeutics Inc. ("XORTX" or the "Company") (CSE:XRX)(OTCQB:XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive...

XRTXF : 0.4387 (-1.50%)
XRX.CN : 4.800 (unch)
XORTX Files New Provisional Patent to Treat and Protect Individuals Most at Risk to Severe Viral Infection

Compositions and Methods for Enhancing Anti-viral Therapies CALGARY, AB / ACCESSWIRE / March 8, 2021 / XORTX Therapeutics Inc. ("XORTX" or the "Company") (CSE:XRX) (OTCQB:XRTXF), a biopharmaceutical company...

XRTXF : 0.4387 (-1.50%)
XRX.CN : 4.800 (unch)
XORTX to Present at BIO CEO and Investor Conference; Strategies to Decrease Acute and Chronic Kidney Injury, Co-morbidity and Mortality

CALGARY, AB / ACCESSWIRE / February 17, 2021 / XORTX Therapeutics Inc. ("XORTX" or the "Company") (CSE:XRX)(OTCQB:XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat...

XRTXF : 0.4387 (-1.50%)
XRX.CN : 4.800 (unch)
XORTX Announces Over Subscribed Private Placement

CALGARY, AB / ACCESSWIRE / February 8, 2021 / XORTX Therapeutics Inc. ("XORTX" or the "Company") (CSE:XRX)(OTCQB:XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat...

XRTXF : 0.4387 (-1.50%)
XRX.CN : 4.800 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

XORTX Therapeutics Inc is focused on developing drug therapies for orphan disease like polycystic kidney disease, and treatment of health consequences caused by chronic high serum uric acid which include cardiovascular disease and diabetes.

See More

Key Turning Points

3rd Resistance Point 4.800
2nd Resistance Point 4.800
1st Resistance Point 4.800
Last Price 4.800
1st Support Level 4.800
2nd Support Level 4.800
3rd Support Level 4.800

See More

52-Week High 10.200
Fibonacci 61.8% 6.739
Fibonacci 50% 5.670
Last Price 4.800
Fibonacci 38.2% 4.601
52-Week Low 1.140

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar